← Back to Screener
Acrivon Therapeutics, Inc. Common Stock (ACRV)
Price$1.86
Favorite Metrics
Price vs S&P 500 (26W)-11.48%
Price vs S&P 500 (4W)-2.26%
Market Capitalization$68.97M
All Metrics
Book Value / Share (Quarterly)$3.56
P/TBV (Annual)0.50x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.06
Price vs S&P 500 (YTD)-30.28%
EPS (TTM)$-2.02
10-Day Avg Trading Volume0.59M
EPS Excl Extra (TTM)$-2.02
EPS (Annual)$-2.02
ROI (Annual)-69.24%
Cash / Share (Quarterly)$3.75
ROA (Last FY)-60.06%
EBITD / Share (TTM)$-2.16
ROE (5Y Avg)-39.87%
Cash Flow / Share (Annual)$-2.06
P/B Ratio0.61x
P/B Ratio (Quarterly)0.68x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-1.53x
ROA (TTM)-51.09%
EPS Incl Extra (Annual)$-2.02
Current Ratio (Annual)7.69x
Quick Ratio (Quarterly)7.57x
3-Month Avg Trading Volume1.35M
52-Week Price Return-3.78%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$6.25
52-Week High$3.56
EPS Excl Extra (Annual)$-2.02
CapEx CAGR (5Y)142.26%
26-Week Price Return-2.73%
Quick Ratio (Annual)7.57x
13-Week Price Return-2.73%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)7.69x
Enterprise Value$27.466
Revenue / Employee (Annual)$0
Cash / Share (Annual)$3.75
3-Month Return Std Dev77.07%
Net Income / Employee (TTM)$-1
ROE (Last FY)-69.24%
EPS Basic Excl Extra (Annual)$-2.02
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.02
ROI (TTM)-57.23%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$7.78
Price vs S&P 500 (52W)-38.88%
Year-to-Date Return-26.14%
5-Day Price Return10.56%
EPS Normalized (Annual)$-2.02
ROA (5Y Avg)-35.43%
Month-to-Date Return28.06%
Cash Flow / Share (TTM)$-2.25
EBITD / Share (Annual)$-2.16
ROI (5Y Avg)-39.87%
EPS Basic Excl Extra (TTM)$-2.02
P/TBV (Quarterly)0.62x
P/B Ratio (Annual)0.68x
Book Value / Share (Annual)$3.56
Price vs S&P 500 (13W)-5.60%
Beta2.00x
Revenue / Share (TTM)$0.00
ROE (TTM)-57.23%
52-Week Low$1.05
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.13
4.13
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ACRVAcrivon Therapeutics, Inc. Common Stock | — | — | — | — | $1.86 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Acrivon Therapeutics is a clinical-stage biopharmaceutical company developing targeted oncology medicines paired with a proprietary proteomics platform designed to identify patients most likely to respond to treatment. Its lead program, prexasertib (ACR-368), is in Phase 2 development. The preclinical pipeline targets DNA damage response and cell cycle regulation pathways.